Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OMVOH 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/OMVOH 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION

Approved

STANDARD

OMVOH 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION

Eli Lilly Nederland B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 27, 2023
Approval ID: 32fb9ce2c6e94317
Company: Eli Lilly Nederland B.V.
Type: Standard

Approval Details

Approval Id: 32fb9ce2c6e94317
Drug Cima Aemps Name: OMVOH 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number: 1231736001
Holder Company Name: Eli Lilly Nederland B.V.
Marketing Company Name: Lilly S.A.
Holder Company Detail Path: /organization/eli-lilly-nederland-bv
Marketing Company Detail Path: /organization/lilly-sa
Authorization Date: 2023-06-27
Dosage Form: CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose: 300 MG
Route Of Administration: VÍA INTRAVENOSA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Eli Lilly Nederland B.V.
Company Detail Path: /organization/eli-lilly-nederland-bv

Company Information

Pharmaceutical Company Name: Eli Lilly Nederland BV
Country Name: Netherlands
Website: http://www.lilly.com/nl

Active Ingredients

MIRIKIZUMAB

300 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 27, 2023

Approval ID

32fb9ce2c6e94317

Type

Standard

Back to CIMA-AEMPS Approvals